/l at days 33 and 37. RBC and platelet transfusion independence were reached at days 50 and 52. Mixed chimerism was demonstrated in blood cells at 1.5, 4 and 6 months after UCBT by molecular biology (VNTR). FISH studies yielded similar results at 15 and 18 months. Twenty months after UCBT, molecular biology showed full donor chimerism. Clinical follow-up (last follow-up: 32 months post transplant) is unremarkable. We suggest that CY and ATG may be a suitable regimen for related HLA-compatible UCBT in patients with SAA. Residual recipient cells can disappear even very late after UCBT, permitting the establishment of complete donor chimerism. Keywords: cord blood transplantation; chimerism; severe aplastic anemia Bone marrow transplantation from HLA-matched siblings has been used successfully as treatment of severe aplastic anemia. A significant gain in survival rate by decreasing graft failure and reducing the risks of GVHD has been obtained with the use of cyclophosphamide and antithymocyte globulin (ATG) as the conditioning regimen and cyclo- 
Case report
The child was a girl born in June 1985. She was 4 1 4 years old at diagnosis (February 1990) . Polymorphonuclear count at diagnosis was 1.5 ϫ 10 9 /l, reticulocyte count was 4.7 ϫ 10 9 /l, platelet count was 32 ϫ 10 9 /l. Other AA causes were eliminated by extensive medullary, cytogenetic, serological, radiological and immunological investigations. No deficiency disease or toxic etiology was found. Platelet and red blood cell transfusion therapy became necessary in August 1990. As there was no HLA-compatible donor amongst her siblings or in the different registries, two courses of anti-lymphocyte globulin (40 mg/kg/day for 4 days), cyclosporine (6 mg/kg/day), and different regimens of corticosteroid therapy were used but remained unsuccessful. The patient's condition progressively worsened with polymorphonuclear counts constantly less than 0.5 ϫ The recipient body weight was 35 kg). Full HLA compatibility was found by serological and molecular biological methods (HLA-A 02/00, B 5/00, DR 06/00, DRw 52). UCB transplantation was decided upon as the transfusion requirements were very high (3 red blood units and 3 platelet units per month).
The conditioning regimen consisted of cyclosphosphamide (50 mg/kg/day, 4 days) and rabbit ATG (30 mg/kg/day, for 4 days) as described. 6 Prevention of GVHD consisted of cyclosporine alone (1.5 mg/kg/day i.v. from day Ϫ1 adjusted on serum levels to 200 ng/ml). UCB cells were thawed and reinjected at day 0 (3 July 1995). No significant toxicity occurred. Hematopoietic recovery is shown in Figure 1 . White blood cells were less than 0.5 ϫ 10 9 /l at day 28. G-CSF (Neupogen, Amgen, Neuilly sur Seine, France) was started. Leukocytes reached 0.5 × 10 9 /l at day 33, 1 × 10 9 /l at day 38, while polymorphonuclear reached 0.5 × 10 9 /l at day 37. The last G-CSF injection was done at day 38. Platelet and red blood cells transfusion independence were reached at day 52 and day 50, respectively. The reticulocyte count reached 50 × 10 9 /l at day 52. The patient was discharged on day 56 without any sign of GVHD. The clinical follow-up was unremarkable. A cytogenetic study performed 1 year after transplantation on bone marrow cells showed complete male chimerism. Red blood cell group studies showed a double A/O population until 17 months post-transplant and a single donor Oϩ red cell population thereafter. FISH studies 7 performed between 15 and 18 months post-transplant revealed that 18-26% of total lymphoid cells, 6-21% of mononuclear cells, 17-20% of CD4 ϩ cells, 21-51% of CD8 ϩ cells, 9-20% of CD14 ϩ cells were of recipient origin (Figure 2 ). Chimerism was tested on blood cells by molecular biology at different time points following transplant. Results are shown in Figure 3 . A mixed chimerism is observed 1.5, 4 and 6 months posttransplant but a complete donor chimerism is observed in the last sample (20 months post-transplant). Cyclosporine was tapered beginning from 1 year after transplantation without relapse. The follow-up in March 1998 was 32 months post-transplant.
Discussion
We report here successful and sustained engraftment in a patient with SAA after a conditioning regimen consisting of cyclophosphamide and ATG. From 17 cord blood cell recipients with bone marrow failure described recently, seven (including our patient) had SAA.
2 Our patient was more than 6 years old, weighed more than 20 kg and had fewer than 37 million nucleated cells infused. These pretransplant characteristics have been found to be unfavorable prognostic factors for survival, GVHD, neutrophil and platelet engraftment after related cord blood transplantation.
2 However, the low number of cells contained in the graft product was sufficient for this patient although G-CSF administration was necessary to prompt myeloid recovery. Cytogenetic studies were consistent with complete donor chimerism but red blood cell phenotyping, molecular biology and FISH studies indicated mixed chimerism for as long as 18 months post-transplant. However, no relapse occurred. Although mixed chimerism is a common finding after transplantation for SAA, especially after conditioning regimens without radiotherapy, 8 our results show that stable mixed chimerism can be achieved without relapse and may ultimately revert to complete donor chimerism. Cyclophosphamide associated with total lymphoid irradiation was used in a patient transplanted with related HLA-matched UCB cells and graft failure was observed. 5 In a similar situation, ATG was used for our patient instead of total lymphoid irradiation and the result seems better. Cyclophosphamide and ATG may be an adequate conditioning regimen for patients with SAA transplanted with HLA-matched related UCB cells.
